Adial Pharmaceuticals announces annual shareholder meeting

Additional proposals cover issuing up to 552,940 shares from Series F warrants, amending the 2017 equity plan, and adopting a 2026 equity plan and 2026 employee stock purchase plan.

Adial Pharmaceuticals will hold its 2026 annual stockholder meeting in September 2026 in Charlottesville, Virginia.

Stockholders are scheduled to vote on issuing 12,930,617 common shares from conversion of Series A Non-Voting Convertible Preferred Stock tied to the Azora acquisition.

Other items include approval to issue up to 1,177,782 shares from assumed Azora options, up to 11,780,948 shares from Initial Closing Pre-Funded Warrants, and up to 23,561,896 shares from Milestone Pre-Funded Warrants and Milestone Incentive Warrants.

Stockholders will also vote on raising authorized common shares to 500,000,000.